Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform.
Speaking at a Bank of America conference, Feider said a “high 30s%” share of new patients in the first quarter were reimbursed through the pharmacy channel. He described that channel as a key driver because patient out-of-pocket costs can be “$25 or less per month,” compared with roughly “$500-$1,500” under durable medical equipment, or DME, reimbursement.
